FDA expands label for GlaxoSmithKline's antiepileptic Lamictal XR
This article was originally published in Scrip
Executive Summary
The US FDA has expanded the label of GlaxoSmithKline's once-daily Lamictal XR (lamotrigine) extended release tablets to include add-on treatment of epilepsy in patients aged 13 years and older with primary generalized tonic-clonic seizures.